Investors need to pay close attention to HROW stock based on the movements in the options market lat

Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatme

Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of op

Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The c

Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report

B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for th

Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperfor

NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of op

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a p

Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing

Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America

Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the larg

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and

U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26

Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate

Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000

Harrow (NASDAQ:HROW) reported quarterly losses of $(0.46) per share which missed the analyst consens

Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter ea

NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of oph

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Comp

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (B

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (B

Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of oph

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America

Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Har

INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch o

Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an F

Harrow relaunches Verkazia for VKC treatment, targeting pediatric eye disease with a steroid-sparing

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, pat

Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo

U.S. stock futures lower, Nasdaq down 200 points. AST SpaceMobile shares dip 11% after reporting wor

Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising gui

Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000

Harrow (NASDAQ:HROW) reported quarterly losses of $(0.74) per share which missed the analyst consens

LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution par

B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and lowers

The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and futu

Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo